A case report of a patient presented with skin ulcer after treatment of lenvatinib
- Authors
- 차세린; 정영걸; 최정완; 김태형; 김승영; 현종진; 정성우; 구자설; 임형준; 김동우
- Issue Date
- Sep-2021
- Publisher
- 대한간암학회
- Keywords
- Lenvatinib mesylate; Skin ulcer; Hepatocellular carcinoma; Adverse drug event; Protein kinase inhibitor
- Citation
- 대한간암학회지, v.21, no.2, pp 194 - 198
- Pages
- 5
- Indexed
- KCI
- Journal Title
- 대한간암학회지
- Volume
- 21
- Number
- 2
- Start Page
- 194
- End Page
- 198
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/54534
- DOI
- 10.17998/jlc.2021.09.20
- ISSN
- 2288-8128
2383-5001
- Abstract
- A 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC) presented to the hospital with pain in the perineal region. He had been taking lenvatinib every day for 2 months after he was diagnosed with HCC with metastases to the lymph node, small bowel mesentery, and retroperitoneal space. Enhanced abdominal computed tomography revealed mild elevation in intensity in the perineal subcutaneous tissue with subcutaneous emphysema. The patient was diagnosed with Common Terminology Criteria for Adverse Events grade 3, skin ulceration of stage IV with full-thickness skin loss and tissue necrosis in the muscular layer. The patient was taken off the medication with prescription of antibiotics, and after 3 weeks, the skin has fully recovered. This is the first report of an HCC patient who presented with a skin ulceration of stage IV after lenvatinib treatment. We recommend stopping the medication immediately and changing to alternative treatments with appropriate supportive care.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.